| Name | Title | Contact Details |
|---|
Eclipse Systems Inc is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TSN Labs Inc is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2004, Direct Flow Medical®, Inc. is focused on developing novel transcatheter heart valve technologies that improve patient outcomes while reducing patient complications. The company is exploring application of its proprietary technology beyond the aortic valve, to the mitral valve and other valve anatomy. Headquartered in Santa Rosa, California, the company also has technology and manufacturing facilities in Lake Forest, California. The Direct Flow Medical TAVI system received the CE Mark in January 2013 and is currently available commercially in Europe. Company Culture: Direct Flow Medical, Inc. has a very unique corporate culture and has developed a set of principles that makes this a unique place to work. Our company is a community, and people feel best when they are proud of their community and know that it is accomplishing something worthwhile. Our employees are encouraged to get to know one another and to support one another in their achievements. We acknowledge and celebrate professional goals as well as personal milestones. The atmosphere at Direct Flow Medical, Inc. is one that supports both a sense of satisfaction from our work, and also a sense of companionship with our co-workers.
Devoted Health is a new healthcare company serving seniors. Our mission is to build a health care plan that treats every member like they were one of our own family. We are devoted to the health and wellness of our members by helping them navigate the healthcare system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.